Septerna, Inc. 4

Daniel D. Long, SVP of Drug Discovery at Septerna, Inc., exercised options for 3,334 shares at $2.76 and sold 3,334 common shares around $34 on August 3, 2026 under a Rule 10b5-1 plan.

On August 3, 2026, Septerna, Inc. SVP of Drug Discovery Daniel D. Long exercised two tranches of stock options for a total of 3,334 shares of common stock at an exercise price of $2.76 per share and concurrently sold 3,334 shares under a pre-arranged Rule 10b5-1 trading plan. The exercises consisted of 1,816 shares from an option expiring November 11, 2033 and 1,518 shares from an option expiring March 19, 2034, with the newly issued shares added to his holdings before the sales were executed. He then sold 1,000 shares at a weighted average price of $33.9756 and 2,334 shares at a weighted average price of $34.6805, for total sale proceeds of roughly $113,000, while remaining a net holder of a substantial equity position. Following these transactions, Long directly owned 96,412 shares of Septerna common stock, which, at approximately $34 per share, represents an equity stake worth about $3.3 million.

Filing Facts

CIK

1984086

Ticker

SEPN

Form

4

Source Type

fda

Accession

0001193125-26-335820

Alert Tier

5